PDF factsheet
      Z

intensive therapy in diabetes type 2 for all type of patients, clinical trials results

glitazone versus conventional treatment
PROactive, 2005
NCT00174993
pioglitazone titrated 15-45 mg daily
versus
standard treatment
patients with type 2 diabetes who had evidence of macrovascular diseasedouble blind
Follow-up duration: 34.5 months
19 countries
insulin detemir versus glargine
Fadini, 2011

versus
insulin glargine plus insulin glulisine versus premixed insulin analogues
Levin, 2011

versus
insulin lispro protamine suspension plus lispro versus glargine plus lispro
Koivisto, 2011

versus
intensive glycemic control versus conventional treatment
ACCORD, 2008
NCT00000620
very intensive glycemic control through currently available means (targetinga glycosylated hemoglobin <6%) during a mean of 3.7 years
versus
standard glycemic control (targeting a glycosylated hemoglobin 7.0-7.9%)
patients with type 2 diabetes mellitus at high risk of death and stroke (pre-existing heart disease or two or more additional risk factors for heart disease)open
Follow-up duration: 3.5y (5y)
USA, Canada
ADDITION, 2010
NCT00237549
intensive multifactorial treatment
versus
routine care
patients with newly diagnosed type 2 diabetes open
Follow-up duration: 5 year
Denmark, United Kingdom, the Netherlands
ADVANCE, 2008
NCT00145925
intensive glucose-lowering treatments HbA1C <=6.5% using gliclazide(modified release) plus other drugs
versus
standard glucose-lowering treatments (targetglycated hemoglobin levels defined on the basisof local guidelines)
patients with type 2 diabetesopen
Follow-up duration: median 5 y
20 countries
Kumamoto (primary prev), 1995
intensive glycemic control with multiple insulin injection treatment
versus
conventional insulin injection treatment (1-2 daily injections)
patients with non-insulin-dependent diabetes mellitus and with no retinopathy and urinary albumin excretions < 30 mg/24 hopen
Follow-up duration: 8.0y
Japan
Kumamoto (secondary prev), 1995
multiple insulin injection treatment
versus
conventional insulin injection treatment (1-2 daily injections)
patients with non-insulin-dependent diabetes mellitus and simple retinopathy open
Follow-up duration: 8.0y
Japan
Steno 2, 2003
targeted, intensified, multifactorial intervention
versus
conventional treatment on modifiable risk factors for cardiovascular disease
patients with type 2 diabetes and microalbuminuriaopen
Follow-up duration: 7.8 y
Denmark
UKPDS 33, 1998
intensive policy with a sulphonylurea (chlorpropamide, glibenclamide, or glipizide) or with insulin; fasting plasma glucose <6.0 mmol/L
versus
conventional policy with diet
newly diagnosed patients with type 2 diabetes who after 3 months’ diet treatment had a mean of two fasting plasma glucose concentrations of 6·1–15·0 mmol/Lopen
Follow-up duration: 10.3 y
UK
VA CSDM, 1997
intensive glycemic control(stepped plan from 1 evening injection of insulin, alone or with glipizide, to multiple daily injections, target to attain near-normal glycemia levels)
versus
standard treatment (1 insulin injection every morning)
non-insulin-dependent diabetes mellitus patientsopen
Follow-up duration: 2.3y
USA
VADT, 2008
NCT00032487
intensive glucose control
versus
standard glucose control
military veterans who had a suboptimal response to therapy for type 2 diabetesopen
Follow-up duration: 5.6y
US

  Options


in first

in second

  Filter